1 September 2021 in World Neurosurgery
14 September 2022 in World Neurosurgery
1 March 2022 in World Neurosurgery
1 October 2019 in JAMA Oncology
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What i
1 April 2021 in The Journal of Heart and Lung Transplantation
The need to reduce in-person clinic visits during the COVID-19 pandemic necessitated a significant reduction in traditional lung transplant surveillance with bronchoscopy and clinic-based pulmonary function testing (PFT). We hypothesized that a screening strategy that utilized cell free DNA (CareDx: Allosure), a non-invasive marker of molecular allograft injury, to determine the need for for-cause diagnostics would yield equivalent lung function stability as traditional monitoring using surveillance bronchoscopy and clinic performed PFTs in lung transplant recipients. We compared the change in FEV1, the prevalence of donor-specific HLA antibodies (DSA), and frequency of hospitalization over parallel 6-month timespans in 2 cohorts of LTRs assessed during the 1st 3 years of their transplant. The 1st cohort (N=65) was monitored from 3/2019 to 9/2019 by in-clinic PFT, surveillance bronchoscopy, DSA, and the 2nd cohort (N=73) was monitored from 3/2020-9/2020 with telemedicine, home spirometry, surveillance dd-cfDNA, and DSA testing every 1-3 months. In cohort 2, patients with >10% decline in home FEV1, and/or dd-cfDNA>1% underwent for-cause bronchoscopy and/or further diagnostic evaluation. Surveillance PFTs were conducted once between 7/20 and 9/20 in cohort 2 to assess the stability of lung function. For both cohorts, a minimum interval of 150 days and a maximum interval of 200 days was used for analysis of spirometric change. There were significantly fewer bronchoscopies/patient (pt) in cohort 2 vs cohort 1 (0.91 vs 1.8, p <0.01). Despite reduced bronchoscopic surveillance, the median % change in FEV1 over 6 months did not differ between cohort 1 vs cohort 2 (1.04% vs 1.01 % p =0.51). Further, there was a comparable prevalence of any level HLA-DSA in cohort 1 vs 2 (32% vs 31% p=0.26). The total incidence of hospitalizations was similar in cohort 1 vs 2 (0.98 events/pt. vs. 1.03 events/pt. P=0.25). The use of non-invasive cell-free DNA testing with home spirometry screening appears to yield comparable medium-term allograft outcomes, as compared to conventional clinic-based PFTs and surveillance bronchoscopy. Further multi-center studies are warranted to determine if this approach can reduce invasive procedures while maintaining equivalent outcomes in clinically meaningful parameters.
7 April 2022 in The Journal of Heart and Lung Transplantation